From Adani Green to Tata Tech: 50 companies swing back to profit in Q4 despite market turmoilIndian companies show strong recovery. Over 50 firms moved from losses to profits in the March quarter. This turnaround happened despite ma...
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...
Bayer bets big on 'self-care' market to deepen India playGlobal pharma major Bayer is significantly expanding its consumer healthcare presence in India, targeting the burgeoning self-care market e...
Stocks in news: Lenskart, Apollo Hospitals, ZEE, BPCL, HindalcoIndian markets navigated a sideways trend, with analysts urging caution until the 24,000 mark is reclaimed. Key stocks like Lenskart, Apoll...
BSE set for Nifty50 hot seat, likely to replace Wipro in September rejigAxis Capital expects BSE to replace Wipro in the NSE’s semi-annual index rebalancing, with changes likely announced in August and effective...
Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
Stocks in news: HAL, TMPV, Bharti Airtel, Anant Raj, Zydus Life, Tata MotorsIndian markets experienced a volatile yet stable session after a sharp sell-off, with the Nifty showing resilience. Key companies like HAL,...
Zydus Lifesciences to raise Rs 5,000 cr via equity; Q2 profit up 38%Zydus Lifesciences plans to raise Rs 5,000 crore via share sales. This move aims to reduce debt and boost future expansion. Funds will supp...
Zydus Lifesciences Q2 Results: Net profit jumps 14% YoY to Rs 911 croreZydus Lifesciences reported a 14% YoY net profit rise to Rs 911 crore for Q2FY25, driven by strong sales in India and the US. Revenue grew ...
Hot Stocks: Brokerages on Zydus Life, Hindalco, Anupam Rasayan and Alkem LaboratoriesMacquarie maintained an underperform rating on Zydus Life with a target price of Rs 490. The Q2FY24 results were a mixed bag.
Zydus Lifesciences Q2 Results: Firm reports 53% YoY jump in net profit at Rs 801 croreRevenue from operations rose 9.1% YoY to Rs 4369 crore in Q2FY24 compared to Rs 4006 crore in Q2FY23. On QoQ revenue declined 15%. The earn...
Buy Zydus Lifesciences, target price Rs 572: Sharekhan by BNP ParibasZydus Lifesciences, incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 48616.16 Crore) operating in Pharmaceu...
Zydus Lifesciences Q1 Results: Net Profit drops 12% YOY to Rs 518 croreThe earnings before interest, tax, depreciation and ammortisation (EBITDA) was Rs 833 crore, a decline of 14.3% YoY. On QoQ, EBITDA rose 16...
Zydus Wellness posts Rs 21-crore profit in Q2 on robust salesRevenue from operations for the second quarter of FY22 stood at Rs 380.13 crore as against Rs 340.32 crore in the year-ago period. The e-co...
Zydus Cadila Q2 net profit up by 94%Besides Lipaglyn, the group launched 19 new products, including line extensions in India of which, four were first in India.
- Cadila Healthcare Q3 net dips by 4.4%, sales rise 20%
Cadila Healthcare, the flagship company of Zydus group, has suffered a 4.4% drop in its third quarter net profit on account of forex losses.
- Zydus Cadila Q2 net drops 40% to Rs 102 crore
The net profit of Zydus dipped to Rs 102.68 crore in second quarter of FY 2011 down from Rs 170.84 crore in the corresponding period last y...